Intuitive Surgical ISRG is being shaped by more than quarterly revenue growth. The company is tied to wider robotic surgery adoption, expansion into minimally invasive diagnostics and deeper use of software inside hospital programs.
Those themes still come with limits. Tariffs, product mix, hospital spending patterns and shifting procedure demand remain important.
ISRG Benefits From Robotic Care Expansion
Intuitive Surgical remains positioned around the move toward minimally invasive and robot-assisted care. Its da Vinci platform supports procedures across general surgery, urology, gynecology, cardiothoracic care, and head and neck specialties.
Worldwide procedures across da Vinci and Ion rose 16% year over year in second-quarter 2026, including 15% growth for da Vinci. Revenue increased 19% to $2.89 billion, supported by procedure volumes, leasing revenues and installed-base expansion. Medtronic plc MDT and Johnson & Johnson JNJ give investors broader medtech comparisons, while ISRG offers a more focused robotic care profile.
Intuitive Surgical Pushes Beyond Surgery With Ion
Ion expands Intuitive Surgical beyond traditional surgery into diagnostic, endoluminal procedures. The flexible, robotic-assisted catheter platform supports minimally invasive lung biopsy, extending the company’s opportunity outside soft tissue surgery. This also helps the company to tap the lucrative lung cancer market.
Ion procedures increased 36% to 48,000 in the quarter, while cumulative procedures exceeded 400,000. Intuitive Surgical placed 55 Ion systems, expanded the Ion installed base 21% year over year to 1,096 systems, and has installed Ion in 12 countries outside the United States.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote
ISRG Turns Software Into a Strategic Asset
Software is becoming a larger part of Intuitive Surgical’s platform value. The company began rolling out the first phase of more than 100 da Vinci 5 updates aimed at telepresence, simulation-based training and care-team workflow.
The My Intuitive+ renewal cycle adds another signal. The company executed its first renewals for offerings covering telepresence, simulation and AI-driven case insights, and no customer in the initial cohort opted out. Better training, workflow support and case insights can make the installed base more useful over time.
Intuitive Surgical Faces Cost and Demand Shifts
The trend story is not one-sided. Intuitive Surgical remains exposed to tariffs, freight, semiconductor memory costs and the mix of newer products. Its second-quarter adjusted gross margin was 70%, helped by a $36 million pretax tariff refund. Excluding that benefit, the margin would have been 68.7%.
Management raised its 2026 adjusted gross margin outlook to 68-69%, but the range still includes an estimated tariff impact equal to 1% of revenues. U.S. da Vinci procedures grew 12% in the quarter, down from 14% in the first quarter, as some benign procedures were deferred. Bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use.
What Trend Signals Mean for ISRG
ISRG’s trend profile remains attractive, but not frictionless. Robotics adoption, Ion lung biopsy growth and digital ecosystem development support the expansion case, while tariffs, capital budgets and procedure mix create constraints.
The current operating picture also makes Zacks Rank and Style Scores important for context. Zacks Rank reflects earnings estimate revision trends, while Style Scores help investors evaluate value, growth and momentum characteristics. A favorable combination is most useful when a stock has a top Zacks Rank and stronger Style Scores.
ISRG’s current Zacks Rank #2 (Buy), Value Score of D, Growth Score of B, Momentum Score of A and VGM Score of B should be checked separately. Investors should pair the company’s trend signals with those indicators before deciding whether the setup supports a bullish or selective stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).